The Neuroblastoma Ras Viral Oncogene HomologQ61 (NRASQ61) mutation, the second most frequent MAPK pathway activating mutation in melanoma, leads to the canonical MAPK pathway activation through RAF dimerization as well as the activation of other parallel pathways, including the phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT) and the mammalian target of rapamycin (mTOR) pathway [11,14,15]. This evidence concerns the gene MTOR and melanoma.